Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 243

1.

Pseudomonas aeruginosa quorum sensing molecules correlate with clinical status in cystic fibrosis.

Barr HL, Halliday N, Cámara M, Barrett DA, Williams P, Forrester DL, Simms R, Smyth AR, Honeybourne D, Whitehouse JL, Nash EF, Dewar J, Clayton A, Knox AJ, Fogarty AW.

Eur Respir J. 2015 May 28. pii: ERJ-02252-2014. doi: 10.1183/09031936.00225214. [Epub ahead of print]

2.

DNA interstrand cross-link repair requires replication-fork convergence.

Zhang J, Dewar JM, Budzowska M, Motnenko A, Cohn MA, Walter JC.

Nat Struct Mol Biol. 2015 Mar;22(3):242-7. doi: 10.1038/nsmb.2956. Epub 2015 Feb 2.

PMID:
25643322
3.

Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial.

Cuzick J, Sestak I, Cawthorn S, Hamed H, Holli K, Howell A, Forbes JF; IBIS-I Investigators.

Lancet Oncol. 2015 Jan;16(1):67-75. doi: 10.1016/S1470-2045(14)71171-4. Epub 2014 Dec 11.

4.

Offering informed choice about breast screening.

Forbes LJ, Ramirez AJ; Expert group on Information about Breast Screening.

J Med Screen. 2014 Dec;21(4):194-200. doi: 10.1177/0969141314555350. Epub 2014 Oct 13.

PMID:
25312639
5.

Repair of a DNA-protein crosslink by replication-coupled proteolysis.

Duxin JP, Dewar JM, Yardimci H, Walter JC.

Cell. 2014 Oct 9;159(2):346-57. doi: 10.1016/j.cell.2014.09.024.

PMID:
25303529
6.

FANCJ promotes DNA synthesis through G-quadruplex structures.

Castillo Bosch P, Segura-Bayona S, Koole W, van Heteren JT, Dewar JM, Tijsterman M, Knipscheer P.

EMBO J. 2014 Nov 3;33(21):2521-33. doi: 10.15252/embj.201488663. Epub 2014 Sep 5.

7.

Comparison of patient reported quality of life and impact of treatment side effects experienced with a taxane-containing regimen and standard anthracycline based chemotherapy for early breast cancer: 6 year results from the UK TACT trial (CRUK/01/001).

Hall E, Cameron D, Waters R, Barrett-Lee P, Ellis P, Russell S, Bliss JM, Hopwood P; TACT Trial Investigators.

Eur J Cancer. 2014 Sep;50(14):2375-89. doi: 10.1016/j.ejca.2014.06.007. Epub 2014 Jul 24.

8.

Appetite stimulants for people with cystic fibrosis.

Chinuck R, Dewar J, Baldwin DR, Hendron E.

Cochrane Database Syst Rev. 2014 Jul 27;7:CD008190. doi: 10.1002/14651858.CD008190.pub2. Review.

PMID:
25064192
9.

Adverse surgical outcomes in screen-detected ductal carcinoma in situ of the breast.

Thomas J, Hanby A, Pinder SE, Ball G, Lawrence G, Maxwell A, Wallis M, Evans A, Dobson H, Clements K, Thompson A; Sloane Project Steering Group.

Eur J Cancer. 2014 Jul;50(11):1880-90. doi: 10.1016/j.ejca.2014.02.023. Epub 2014 May 26.

PMID:
24874088
10.

The management of acute coronary syndrome patients across New Zealand in 2012: results of a third comprehensive nationwide audit and observations of current interventional care.

Ellis C, Gamble G, Devlin G, Elliott J, Hamer A, Williams M, Matsis P, Troughton R, Ranasinghe I, French J, Brieger D, Chew D, White H; New Zealand Acute Coronary Syndromes (NZACS) SNAPSHOT Audit Group.

N Z Med J. 2013 Dec 13;126(1387):36-68.

PMID:
24362734
11.

Comparison of mammographic findings after intraoperative radiotherapy or external beam whole breast radiotherapy.

Elsberger B, Romsauerova A, Vinnicombe S, Whelehan P, Brown DC, Dewar JA, Thompson AM, Evans A.

Eur J Surg Oncol. 2014 Feb;40(2):163-7. doi: 10.1016/j.ejso.2013.11.011. Epub 2013 Dec 4.

PMID:
24332581
12.

Progesterone receptor expression is an independent prognostic variable in early breast cancer: a population-based study.

Purdie CA, Quinlan P, Jordan LB, Ashfield A, Ogston S, Dewar JA, Thompson AM.

Br J Cancer. 2014 Feb 4;110(3):565-72. doi: 10.1038/bjc.2013.756. Epub 2013 Dec 3.

13.

Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trial.

Vaidya JS, Wenz F, Bulsara M, Tobias JS, Joseph DJ, Keshtgar M, Flyger HL, Massarut S, Alvarado M, Saunders C, Eiermann W, Metaxas M, Sperk E, Sütterlin M, Brown D, Esserman L, Roncadin M, Thompson A, Dewar JA, Holtveg HM, Pigorsch S, Falzon M, Harris E, Matthews A, Brew-Graves C, Potyka I, Corica T, Williams NR, Baum M; TARGIT trialists' group.

Lancet. 2014 Feb 15;383(9917):603-13. doi: 10.1016/S0140-6736(13)61950-9. Epub 2013 Nov 11. Erratum in: Lancet. 2014 Feb 15;383(9917):602.

14.

The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials.

Haviland JS, Owen JR, Dewar JA, Agrawal RK, Barrett J, Barrett-Lee PJ, Dobbs HJ, Hopwood P, Lawton PA, Magee BJ, Mills J, Simmons S, Sydenham MA, Venables K, Bliss JM, Yarnold JR; START Trialists' Group.

Lancet Oncol. 2013 Oct;14(11):1086-94. doi: 10.1016/S1470-2045(13)70386-3. Epub 2013 Sep 19.

PMID:
24055415
15.

Beware using secular trends in deaths to judge effectiveness of breast screening.

Brewster DH, Bhatti LA, Thomson CS, Cameron DA, Dewar JA.

BMJ. 2013 Jul 10;347:f4335. doi: 10.1136/bmj.f4335. No abstract available.

PMID:
23842431
16.

The benefits and harms of breast cancer screening: an independent review.

Marmot MG, Altman DG, Cameron DA, Dewar JA, Thompson SG, Wilcox M.

Br J Cancer. 2013 Jun 11;108(11):2205-40. doi: 10.1038/bjc.2013.177. Epub 2013 Jun 6. Review. No abstract available.

17.

Cohort study of adherence to adjuvant endocrine therapy, breast cancer recurrence and mortality.

Makubate B, Donnan PT, Dewar JA, Thompson AM, McCowan C.

Br J Cancer. 2013 Apr 16;108(7):1515-24. doi: 10.1038/bjc.2013.116. Epub 2013 Mar 21.

18.

Chromosome biology: conflict management for replication and transcription.

Dewar JM, Walter JC.

Curr Biol. 2013 Mar 4;23(5):R200-2. doi: 10.1016/j.cub.2013.01.054.

19.

Independent UK Panel on Breast Cancer Screening replies to Michael Baum.

Marmot M; Independent UK Panel on Breast Cancer Screening, Altman G, Cameron DA, Dewar JA, Thompson SG, Wilcox M.

BMJ. 2013 Feb 13;346:f873. doi: 10.1136/bmj.f873. No abstract available.

PMID:
23407732
20.

Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial.

Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, Abraham M, Medeiros Alencar VH, Badran A, Bonfill X, Bradbury J, Clarke M, Collins R, Davis SR, Delmestri A, Forbes JF, Haddad P, Hou MF, Inbar M, Khaled H, Kielanowska J, Kwan WH, Mathew BS, Mittra I, Müller B, Nicolucci A, Peralta O, Pernas F, Petruzelka L, Pienkowski T, Radhika R, Rajan B, Rubach MT, Tort S, Urrútia G, Valentini M, Wang Y, Peto R; Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group.

Lancet. 2013 Mar 9;381(9869):805-16. Erratum in: Lancet. 2013 Mar 9;381(9869):804.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk